openPR Logo
Press release

Rheumatoid Arthritis Treatment Market

06-14-2017 05:20 PM CET | Health & Medicine

Press release from: Pharmaceutical By CMI

/ PR Agency: `

Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the most. Treatments available for rheumatoid arthritis aids to relive symptoms and improve the joint function. A comprehensive treatment for RA usually involves integration of patient education, exercise, medications, and surgery (occasionally). The rheumatoid arthritis treatment market can be analyzed based on the drug type, as follows:
Biological drugs
Monoclonal antibodies
Non-Biologicals
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Analgesics
Disease-modifying anti-rheumatic drugs (DMARDs)
IL-6 inhibitors
TNF inhibitors
NSAIDs and corticosteroid are also the first-line fast acting therapeutic drugs. Acetylsalicylate, naproxen, ibuprofen, etodolac, and diclofenac are the NSAIDs usually prescribed as first-line drugs for RA. These drugs reduce inflammation, and pain. Corticosteroid medications are given either orally or parenterally to reduce inflammation and restore joint mobility and function. These class of drugs are more potent than NSAIDs and therefore usually preferred a first line therapy by prescribers. The global rheumatoid arthritis treatment industry is expected to be driven considerably in near future by DMARDs that form second line slow-acting therapeutic drugs. Longer therapeutic regimen with these drugs increases cost of therapy and also promote remission of joint destruction and deformity. Methotrexate is the most commonly prescribed second line drug for RA and hence, occupies major share in the respective segment of global rheumatoid arthritis treatment market. Tofacitinib (Xeljanz) is the most potential FDA approved Janus kinase (JAK) inhibitor available in the global market of rheumatoid arthritis treatment.

FDA approved biologic drugs include rituximab (Rituxan, MabThera), abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel), certolizumab (Cimzia), anakinra (Kineret), infliximab (Remicade), golimumab (Simponi), and tocilizumab (Actemra). Besides these approved drugs, biosimilars in pipeline would fuel the rheumatoid arthritis treatment market growth in near future.

Request a sample copy of this report@
https://www.coherentmarketinsights.com/insight/request-sample/166

Key statistics pertaining to the global rheumatoid arthritis treatment market:
Over time, there is damage to cartilage and mobility function of the affected joint in rheumatoid arthritis patient.
Affects nearly 1.3 million U.S. population (RheumatoidArthritis.org)
Most common in the age group of 30-60 years
Global prevalence varies in the range of 0.3% to 1% (World Health Organization)
Average annual cost of treatment may go up to US $20,000 (RheumatoidArthritis.org)
According to the Arthritis Foundation, people with RA loose more workdays compared to those affected by any other medical condition
According to a Harvard University study published in the Journal of Global Health (2017), prevalence of rheumatoid arthritis in Southeast Asian countries was 0.4%, 0.42 in western Pacific region, and 0.37% in eastern Mediterranean countries

Plethora of research work to introduce effective treatment therapies in the global rheumatoid arthritis treatment market
Introduction of newer therapies are expected to fuel growth of rheumatoid arthritis treatment market in developed nations. Emerging economies are late adapters to new technologies and therapies, thus are potential markets for brands not yet marketed in these countries. The Chinese FDA recently approved Xeljanz for RZ treatment (2017). The product is awaiting approval from the EU. Among the Asian countries, India, China, Pakistan, and Bangladesh had major prevailing rheumatoid arthritis patients as per WHO–ILAR COPCORD (International League of Associations for Rheumatology) (Community Oriented Program for Control of Rheumatic Diseases) studies (2015).

Some of the products in pipeline include:

Antibodies that target collagen II, an important protein in joint cartilage (Researchers at the Department of Immunology, Genetics and Pathology, Uppsala University, Sweden)
Stem cell I.V. therapy developed by Mesoblast Ltd. to treat RA patients unresponsive to TNF drugs (phase 2 trials)
More of such developments by the market players will be a significant contributor towards the growth of global rheumatoid arthritis treatment industry.
Some of the major players in the global rheumatoid arthritis treatment market are Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,

Get Mor e details about this report@
https://www.coherentmarketinsights.com/ongoing-insight/rheumatoid-arthritis-treatment-market-166

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Coherent Market Insights Blog @ https://blog.coherentmarketinsights.com
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rheumatoid Arthritis Treatment Market here

News-ID: 578932 • Views: 239

More Releases from Pharmaceutical By CMI

Southern Blotting Market: Global Industry Insights Analysis and Opportunity Asse …
North America to dominate the southern blotting market owing to increased government funding and availability of technologies in the region The southern blotting market report covers market analysis across regions – North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Global southern blotting market is witnessing a positive trend with North America and Europe as the main engine of growth. North America and Europe are expected to capture a major
Ulcerative Colitis Market
Ulcerative colitis is the most common type of inflammatory bowel disease that affects the colon (lining of the large intestine) and rectum. The inflammation produces tiny sores called ulcers. These disease can affect people of any age, though prevalence is especially high among people under 30 years of age. The major symptoms of this disease are diarrhea, belly pain/cramps, bleeding from the rectum, also other indications are sudden and unexplained
Pet Health Products Market
A pet or companion animal is an animal kept primarily for one's company, protection, or entertainment. Popular pets are regularly noted for their attractive appearances and their loyal or playful personalities. While dogs and cats are the most preferred pet animals, people also keep house rabbits, fancy rats, guinea pigs, parrots, chickens, and aquatic pets. The trend of pet adoption and keeping is gaining rapid traction across the globe. The
Prefilled Syringes Market
Parenteral drugs are the second most preferred type of drugs after oral solid dosage forms and also holds second largest market share in terms of revenue in overall pharmaceutical market. Various benefits such as ease in administration, better patient compliance and 100% bioavailability are the few important factors that are expected to favor growth of the prefilled syringes market over the forecast period (2016–2024). Prefilled syringes segment is the one

All 5 Releases


More Releases for NSAIDs

NSAIDs Drug Global Industry Report - History, Present and Future 2018
GET SAMPLE REPORT @ https://www.research2reports.com/sample-report-pharmaceuticals/nsaids-drug-market/71856 The global market size of NSAIDs Drug is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the end of 2023 with a CAGR of XX% from 2018 to 2023. There are 3 key segments covered in this report: geography segment, end use/application segment and competitor segment. For geography segment, regional supply, application-wise and type-wise demand,
EMEA (Europe, Middle East and Africa) NSAIDs Market Report 2017
MarketResearchReports.Biz presents this most up-to-date research on "EMEA (Europe, Middle East and Africa) NSAIDs Market Report 2017" Description In this report, the EMEA NSAIDs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K MT), revenue
Global NSAIDs Market Drivers, Trends and Opportunities Forecasts from 2017 to 20 …
Executive Summary Global NSAIDs Market: WiseGuyReports.com adds “NSAIDs Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022”reports to its database. WiseGuyReports.Com Publish a New Market Research Report On – Request a Sample Report @ https://www.wiseguyreports.com/sample-request/953118-global-nsaids-market-research-report-2017 In this report, the global NSAIDs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between
NSAIDs: Recent Study including Growth Factors, Applications, Regional Analysis, …
The Global NSAIDs Market Research Report 2017 renders deep perception of the key regional market status of the NSAIDs Industry on a Global level that primarily aims the core regions which comprises of continents like Europe, North America, and Asia and the key countries such as United States, Germany, China and Japan. Request for sample of NSAIDs Market research report @ https://www.qyresearchgroups.com/request-sample/392752 The report on “Global NSAIDs Market” is a professional report
Global Pain Management Drugs Market Type(Opioids, NSAIDs, Anti-Migraine, Anticon …
Over the recent years, the global pain management drugs industry has been growing rapidly with the increasing demand for drugs which are used for the treatment of chronic pain conditions of neck, lower back, shoulders, post-operative pain, and pain during the sports injuries. Globally, the growth in the pain management drugs market is driven by large number of chronically ill patients, rise in global incidences of cancer and strong presence
Global NSAIDs Sales Market Report 2017
This report studies sales (consumption) of NSAIDs in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Bayer (DE) Novacap (FR) Abbott Pfizer Inc Geri-Care Pharmaceuticals Perrigo Company Kopran Ltd. Merck Sharp & Dohme Corp. Sun Pharmaceutical Industries Ltd GlaxoSmithKline Reddy Pharmaceuticals Ltd Johnson & Johnson Request for Sample of Premium Research Report @ http://www.qyresearchreports.com/sample/sample.php?rep_id=962754&type=E Market Segment by Regions, this report splits